ProCE Banner Activity

Updated Analysis From the Phase III MEDALIST Trial of Luspatercept to Treat Anemia in Lower-Risk RBC Transfusion-Dependent MDS With Ring Sideroblasts

Slideset Download
Conference Coverage
Longer-term analysis of the MEDALIST study showed that more luspatercept-treated patients attained transfusion independence for ≥ 8 weeks any time during therapy compared with placebo.

Released: December 15, 2019

Expiration: December 13, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company